Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
Autore:
Cannon, GW; Caldwell, JR; Holt, P; McLean, B; Seidenberg, B; Bolognese, J; Ehrich, E; Mukhopadhyay, S; Daniels, B;
Indirizzi:
Merck & Co Inc, Rahway, NJ 07065 USA Merck & Co Inc Rahway NJ USA 07065Merck & Co Inc, Rahway, NJ 07065 USA Univ Utah, Salt Lake City, UT USA Univ Utah Salt Lake City UT USAUniv Utah, Salt Lake City, UT USA Dept Vet Affairs Med Ctr, Salt Lake City, UT USA Dept Vet Affairs Med CtrSalt Lake City UT USA r, Salt Lake City, UT USA
Titolo Testata:
ARTHRITIS AND RHEUMATISM
fascicolo: 5, volume: 43, anno: 2000,
pagine: 978 - 987
SICI:
0004-3591(200005)43:5<978:RASIOC>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN G/H SYNTHASE-1; DIFFERENTIAL INHIBITION; SELECTIVE-INHIBITION; OSTEO-ARTHRITIS; COX-2; RISK; CLASSIFICATION; INFLAMMATION; IBUPROFEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Daniels, B Merck & Co Inc, 126 E Lincoln Ave,RY 32-637, Rahway, NJ 07065 USA Merck & Co Inc 126 E Lincoln Ave,RY 32-637 Rahway NJ USA 07065
Citazione:
G.W. Cannon et al., "Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip", ARTH RHEUM, 43(5), 2000, pp. 978-987

Abstract

Objective. To compare the clinical efficacy of rofecoxib, a specific inhibitor of cyclooxygenase 2 (COX-2), with that of diclofenac in patients with osteoarthritis (OA) and to evaluate the safety and tolerability of rofecoxib. Methods. We performed a randomized, double-blind, active comparator-controlled trial in 784 adults with OA of the knee or hip. Patients were randomized to 1 of 3 treatment groups: 12.5 mg of rofecoxib once daily, 25 mg of rofecoxib once daily, and 50 mg of diclofenac 3 times daily. Clinical efficacy and safety were evaluated over a 1-year continuous treatment period. Results. Rofecoxib at dosages of 12.5 and 25 mg demonstrated efficacy that was clinically comparable to that of diclofenac, as assessed by all 3 primary end points according to predefined comparability criteria. Results from secondary end points were consistent with those of the primary end points. There were small statistical differences favoring diclofenac for 2 of the end points. All treatments were well tolerated. Conclusion. Rofecoxib was well tolerated and provided efficacy that was clinically comparable, according to predefined statistical criteria, to that of 150 mg of diclofenac per day in this 1-year study. Specific inhibition of COX-2 provided therapeutic efficacy in OA.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/07/20 alle ore 11:09:47